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Protein misfolding cyclic ampliﬁcationolding cyclic ampliﬁcation (sPMCA) to amplify the D10 strain of CWD prions in a
linear relationship over two logs of D10 dilutions. The resultant PMCA-ampliﬁed D10 induced terminal TSE
disease in CWD-susceptible Tg(cerPrP)1536 mice with a survival time approximately 80 days shorter than the
original D10 inoculum, similar to that produced by in vivo sub-passage of D10 in Tg(cerPrP)1536 mice. Both in
vitro-ampliﬁed and mouse-passaged D10 produced brain lesion proﬁles, glycoform ratios and conformational
stabilities signiﬁcantly different than those produced by the original D10 inoculum in Tg(cerPrP)1536 mice.
These ﬁndings demonstrate that sPMCA can amplify and adapt prion strains in vitro as effectively and much
more quickly than in vivo strain adaptation by mouse passage. Thus sPMCA may represent a powerful tool to
assess prion strain adaptation and species barriers in vitro.
© 2008 Elsevier Inc. All rights reserved.Introduction
According to the prion hypothesis, a proteinacious pathogen
devoid of instructional nucleic acid initiates and propagates transmis-
sible spongiform encephalopathies (TSEs), a group of invariably fatal,
infectious neurological diseases (Prusiner, 1982) characterized by
auto-conversion of the normal host cellular prion protein (PrPC) into a
misfolded, insoluble, proteinase K (PK)-resistant form (PrPRES).
Mounting biochemical and biological evidence supports the prion
hypothesis (Büeler et al., 1993; Hope et al., 1986; Oesch et al., 1985;
Prusiner, 1982). Prion infectivity correlates with PrPRES in brain
homogenates from animals afﬂicted with TSEs, including sheep
scrapie, bovine spongiform encephalopathy (BSE) and chronic wasting
disease (CWD, (Bolton et al., 1982; Browning et al., 2004; Collinge et
al., 1995a; Hope et al., 1988; Race et al., 2002; Scott et al., 1999). More
recently, synthetic prions made from truncated recombinant PrP have
been shown to be infectious when inoculated into transgenic mice
expressing the same isoform and in wild type mice upon subsequent
passage (Legname et al., 2004). Additional evidence has come from
several reports that demonstrate in vitro generation of infectious
hamster prions using serial protein misfolding cyclic ampliﬁcation
(sPMCA), a highly efﬁcient ampliﬁcation method employing repeated
cycles of incubation of prions with normal brain homogenate (NBH) as
a source of PrPC substrate to grow existing prion templates, andel).
l rights reserved.sonication to break the resulting large aggregates into smaller, more
numerous prion templates (Castilla et al., 2005; Deleault et al., 2007;
Murayama et al., 2007a; Weber et al., 2007). sPMCA of PrPRES from
mouse-adapted scrapie (PrPSc) and CWD prions (PrPCWD) has recently
been described (Kurt et al., 2007; Murayama et al., 2007b), although
infectivity of these ampliﬁed materials was not assessed.
The unique etiology of mammalian prion diseases complicates
characterization, identiﬁcation, and even the deﬁnition of prion
strains. Traditionally, prion strains have been typed according to
host range, incubation time to terminal disease and neuroanatomic
lesion proﬁles based on seminal work comparing human and animal
TSEs (Gajdusek et al., 1966; Gibbs and Gajdusek, 1971; Hadlow, 1959;
Taraboulos et al., 1992). Other criteria have been developed based on
biochemical and biophysical properties of prions to investigate
heritable structural differences among different prion strains, includ-
ing size and extent of the PK-resistant core (Bessen and Marsh, et
al.1994; Korth et al., 2003; Telling et al., 1996), glycoform ratio and
conformational stability upon chemical or thermal denaturation
(Collinge et al., 1996; Hill et al., 1997; Peretz et al., 2001, 1997; Safar
et al., 1993, 1998; Scott et al., 2005). These parameters have proven
useful for identiﬁcation of prion strains with similar origins, host
ranges and pathology and to predict transmission barriers to hetero-
logous host species (Collinge and Rossor, 1996; Raymond et al., 2000;
Will et al., 1996).
Experimental inoculation of animals represents the most reliable
and accepted measure of efﬁciency of strain adaptation and trans-
mission of prions into new hosts (Collinge et al., 1995a, 1995b; Hamir
et al., 2005, 2006a, 2006b, 2003). However, these experiments often
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experimental standards, to fully assess strain adaptation and species
barriers. Here we report efﬁcient linear ampliﬁcation of PrPCWD by
sPMCA resulting in in vitro generation of infectious CWD prions.
Remarkably, we observed a drastic, nearly identical reduction in
incubation time to terminal disease of CWD-susceptible Tg(cerPrP)
1536 mice inoculated with in vitro-ampliﬁed or mouse-passaged
prions from the D10 isolate of CWD prions when compared to the
original D10 inoculum. In vitro-ampliﬁed and in vivo-passaged D10
also shared similar neuropathological and biochemical characteristics
that were signiﬁcantly different than the original D10 strain, more
closely resembling the RML strain of mouse-adapted scrapie prions.
By all accepted parameters used to characterize prion strains that we
examined, sPMCA adapted the D10 CWD strain as efﬁciently as
passage in Tg(cerPrP)1536 mice, and represents a powerful, efﬁcient
tool for assessing strain adaptation and species barriers in vitro.
Results
Linear ampliﬁcation of PrPCWD
In vitro ampliﬁcation of PK-resistant PrP (PrPRES) from CWD prions
using protein misfolding cyclic ampliﬁcation (PMCA) has recently
been reported (Kurt et al., 2007). We extend this work in several ways.
We ﬁrst tested whether NBH expressing heterologous PrPC could be
used to amplify PrPRES. We performed PMCA of D10 and RML serially
diluted into NBH from wild type FVB mice (Fig. 1A) and TgA20 mice
expressing 4–5-fold more mouse PrPC (moPrPC, Fig. 1B). Both moPrPC
substrates supported ampliﬁcation of scrapie PrPRES (PrPSc), but not
CWD PrPRES (PrPCWD). We then performed PMCA on D10 and RML
samples serially diluted into Tg(cerPrP)1536 NBH expressing ﬁve-fold
more cervid PrPC (cerPrP) than FVB mice express moPrPC (C). After
PMCA we detected a 6×106-fold dilution of PrPCWD (lane 8), whose
band intensity matched that of the 9×102-fold dilution of unampliﬁed
D10 (lane 3), thus yielding an approximately 6666-fold increase in
PrPCWD. Tg(cerPrP)1536 NBH failed to support PrPSc ampliﬁcation.
Quantitative analyses of band intensities from three experiments
demonstrated a consistent, rapid decrease in band intensity ofFig. 1. Protein misfolding cyclic ampliﬁcation of chronic wasting disease prions. Three-fold s
lanes 1–9) or RockyMountain lab strain of mouse-adapted scrapie prions (RML, lane 10) dilut
subjected to 96 cycles of PMCA (lanes 4–10). Proteinase K (PK) digestion andwestern blotting
not PrPCWD (lanes 4–9) ampliﬁcation, whereas Tg(cerPrP)1536 NBH (C) efﬁciently ampliﬁed P
ampliﬁcation after one PMCA round (compare lanes 3 to 8). Molecular weight markers are sh
dramatic decrease in signal intensity upon dilution of D10 without PMCA, and sustained inte
D10 dilution reveals a linear relationship over two logs of D10 dilutions. Data are representunampliﬁed PrPCWD dilutions, with complete loss of signal at 10−3
dilutions (D). Plotting −fold ampliﬁcation as a function of −fold
dilution of D10 on a log–log scale reveals a linear relationship between
103 and 2×105-fold dilution of D10 (E).
sPMCA or mouse passage of D10 shortens mean incubation time to
terminal prion disease
To determine whether ampliﬁed PrPCWD is infectious, we used
serial PMCA (sPMCA) to generate PrPCWD in vitro. From our
quantiﬁcation data, repeated 10−3 dilution and ampliﬁcation should
maintain sPMCA in the linear range of PrPCWD ampliﬁcation (Fig. 1E).
Beginning with a 10−3 D10 dilution, we achieved a ten-fold
ampliﬁcation efﬁciency after one PMCA round, producing PrPCWD
equivalent to a 10−2 dilution. Re-diluting this material 103-fold
produced a 10−5 dilution equivalent. We then ampliﬁed this material
approximately 103-fold, again producing a 10−2 equivalent dilution.
We continued this sPMCA strategy for six more rounds, oscillating
between 10−5 and 10−2 equivalent dilutions upon re-dilution and
PMCA to arrive at an overall D10 dilution of 10−24, a point at which the
original PrPRES inoculum has been estimated to be lost, and only
ampliﬁed PrPRES is present in the sample (Castilla et al., 2005).
Western blot analysis demonstrated the maintenance of a strong
PrPRES signal in the ampliﬁed product throughout sPMCA, whereas
unampliﬁed samples were undetectable (Fig. 2A). Densitometric
analysis revealed similar band intensities for PK-digested D10,
ampliﬁed 10−24 D10 and mouse-passaged D10, with RML producing
approximately half the intensity of the other three inocula (Fig. 2B).
We therefore inoculated Tg(cerPrP)1536 mice intracerebrally with
30 μl of each D10-derived inoculum diluted 1:10 in sterile 320 mM
sucrose supplemented with antibiotics in PBS. All mice inoculated
with ampliﬁed D10 contracted neurologic disease consistent with TSE
with a mean incubation time to terminal illness of 169±4 days post
inoculation (DPI), while all mice inoculated with unampliﬁed D10 are
currently asymptomatic at N500 DPI (Table 1). Surprisingly, Tg(cerPrP)
1536 mice inoculated with the original D10 strain contracted disease
82 days later (251±3 DPI) than ampliﬁed D10-inoculated mice.
Inoculation of Tg(cerPrP)1536 mice with mouse-passaged D10 (D10erial dilutions of infected brain homogenate from the D10 isolate of CWD prions (D10,
ed 1:3×102 into normal brain homogenate (NBH) were either snap-frozen (lanes 1–3) or
of samples reveal that wild type NBH (A) or TgA20 NBH (B) supported PrPSc (lane 10), but
rPCWD (lanes 4–9), but not PrPSc (lane 10), resulting in approximately 6666-fold PrPCWD
own in kDa to the left of the blots. (D) Quantiﬁcation of band intensities demonstrates a
nsity to 6×106-fold dilution with PMCA. (E) Plotting −fold ampliﬁcation as a function of
ative of at least three independent experiments.
Table 1
Strain adaptation of CWD prions
Inoculuma Tg1536 Wild type
Incidenceb DPI±SDc Incidence DPI±SD
Ampliﬁed 10–24 D10 6/6 169±4d NDe ND
Unampliﬁed 10–24 D10 0/8 N500 ND ND
D10 8/8 251±3 0/5 N500
D10 Passage 1 6/6 171±3d ND ND
RML 5.0 0/6 N300 10/10 156±8
a Mice were inoculated intracerebrally.
b Incidence=number of terminally sick mice/number of animals inoculated.
c DPI±SD, days post inoculation to terminal disease±standard deviation.
d pb0.01 compared to Tg1536 inoculated with D10.
e ND, no data.
Fig. 2. (A) Serial PMCA sustains CWD prion ampliﬁcation. A 103-fold dilution of D10 was
subjected to serial PMCA (sPMCA). After each round, the sample was re-diluted 1:103 in
fresh NBH and subjected to an additional 96 PMCA cycles. Fold-dilutions refer to the
overall dilution relative to the starting dilution and were detected at the indicated
round. Unampliﬁed samples at each dilution (U) and unspiked normal brain (NB) were
not detected. (B) Western blot signal intensity comparison of 10, 20 and 40-fold
dilutions of ampliﬁed D10, original D10, mouse-passaged D10 and RML inocula.
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3 DPI) that closely matched the incubation time for ampliﬁed D10-
inoculated mice. Wild type mice inoculated with D10 and Tg(cerprP)
1536 mice inoculated with RML are currently asymptomatic at N500
and 300 DPI, respectively. Wild type mice inoculated with 30 μL of
RML contracted scrapie 156±8 DPI, which is very similar to incubation
times observed for mice inoculated with in vitro-ampliﬁed and
mouse-adapted D10. Taken together, these data comparing primary
passage of ampliﬁed D10, primary passage of D10 and secondary D10
passage using mean incubation time to terminal disease, the accepted
benchmark for prion strain characterization, strongly suggest that
strain adaptation of D10 CWD prions occurred in vitro and in vivo.
However, because PrPRES concentration does not always directly
correlate with prion infectivity (Hill et al., 1999; Rubenstein et al.,
1994), normalizing prion inoculum by estimating PrPRES content may
have resulted in imprecise measurement of prion doses that could
explain the differences in mean incubation times that we observed in
the mouse bioassay. We therefore analyzed these inocula by neuro-
pathological and biochemical criteria previously used to assess other
prion strain properties.
sPMCA and mouse passage of D10 changes CWD neuropathology
To compare CWD neuropathology of terminally sick mice inocu-
lated with in vitro-ampliﬁed and mouse-passaged D10 to mice
inoculated with the original D10 strain, we analyzed brain sections
for vacuolation, astrogliosis, PrPRES deposition and amyloidogenicity
(Fig. 3). Brains of Tg(cerPrP)1536 mice inoculated with ampliﬁed D10
(Amp D10 p1 mice) exhibited little to no neuronal cell loss (Fig. 3A),
mild vacuolation (Figs. 3A–C), disseminated astrogliosis (Fig. 3B) and
diffuse PrPCWD deposits (Fig. 3C) in the hippocampal region (Figs. 3A–
C). These deposits stained poorly with Thioﬂavin T (Fig. 3D), indicating
little or no amyloid structure. We observed increased neuropathology
in the cerebellum, with more vacuolation (Figs. 3E–G), astrogliosis
(Fig. 3F) and PrPRES deposition (Fig. 3G). Thioﬂavin T stained a few
deposits, revealing some amyloid structure (Fig. 3H). In contrast,
hippocampal sections of Tg(cerPrP)1536mice inoculated with original
D10 inoculum (D10 p1 mice) displayed extremely severe vacuolation
(Figs. 3I–K), neuronal cell loss (Fig. 3I) and astrogliosis (Fig. 3J).
Numerous PrPCWD deposits appeared more focal and dense (Fig. 3K)and Thioﬂavin T stained these punctate plaques sharply, revealing a
more deﬁned, radially organized amyloid structure (Fig. 3L). However,
little or no cerebellar neuropathology was evident in these mice
compared to Amp D10 p1 mice (Figs. 3M–P). Upon secondary passage
of D10 (D10 p2 mice), we observed decreased neuropathology in the
hippocampus similar to that found in Amp D10 p1 mice, with little or
no vacuolation or neuronal cell loss (Figs. 3Q–S). The mild to moderate
astrogliosis observed (Fig. 3R) was dramatically decreased compared
to D10 p1mice. Little or no PrPRES depositionwas evident (Fig. 3S) and
no Thioﬂavin T positive staining was observed (Fig. 3T). In the
cerebellum, we observed an increase in vacuolation, neuronal cell loss
(Figs. 3U–W) and astrogliosis (Fig. 3V). We also observed faintly
stained, diffuse PrPCWD deposits (Fig. 3W), some of which were
stained by Thioﬂavin T (Fig. 3X). These rare amyloid structures
appeared more diffuse and lacked the radially structured punctae
clearly evident in amyloid from D10 p1 mice (Fig. 3L). Hippocampal
sections of wild type mice inoculated with RML exhibited vacuolation,
neuronal cell loss (Fig. 3Y), astrogliosis (Fig. 3Z) and diffuse PrPSc
deposition (Fig. 3AA) typical of mouse scrapie and reminiscent of
neuropathology observed in Amp D10 p1 and D10 p2 brains.
We examined eight additional brain areas for neuropathology to
generate lesion proﬁles for each inoculation group. We observed
increased neuropathology, especially diffuse PrPRES deposition and
vacuolation, in the dorsal medulla and cerebellum, with moderate to
severe astrogliosis in the superior colliculus, red nucleus and thalamus
in ampliﬁed and mouse-passaged D10-inoculated Tg(cerPrP)1536
mice and RML-inoculated wild type mice. We observed decreased
overall neuropathology in these brain regions, and increased
neuropathology in the hippocampus of Tg(cerPrP)1536 mice inocu-
lated with the original D10 srain. Seven lesion proﬁle scores for brains
from Amp D10 p1, ﬁve for D10 p2 and six for RML infected mice
differed from D10 p1 scores without overlapping standard deviations
(SDs); while ≤3 lesion proﬁle scores differed without overlapping SDs
among brains from Amp D10 p1, D10 p2 and RML infected mice (Fig.
4). Overall lesion severity also increased and neuroanatomic location
was altered from D10 p1 to D10 p2 and Amp D10 p1 to more closely
match severity and location of RML-induced lesions. Taken together,
these data indicate that in vitro ampliﬁcation and in vivo-passage of
D10 changes CWD neuropathology to one that more closely resembles
scrapie neuropathology in mice and further support the proposition
that D10 strain adaptation has occurred in vitro and in vivo.
sPMCA and mouse passage of D10 changes PrPCWD glycoforms ratios
We next characterized these prion inocula biochemically by
assessing PK-resistant fragment sizes and glycoform ratios, which
have previously been used to characterize prion strains (Collinge et al.,
1996; Hill et al., 1997). While analysis of pooled brain homogenate
from at least three mice from each group or three PMCA reactions
revealed no differences in PK-resistant core fragment sizes, we did
detect signiﬁcant differences in glycoform ratios (Fig. 5A). RML
Fig. 3. Strain adaptation changes CWD neuropathology. Brain sections from terminally sick Tg(cerPrP)1536 and wild type mice were assessed for vacuolation (H&E), astrogliosis
(GFAP), PrPRES deposition (PrPRES) and amyloidogenicity (ThioT). Boxed areas in the PrPRES panels are shown stained with Thioﬂavin T to the right. Hippocampal sections from mice
inoculated with ampliﬁed D10 exhibited little or no neuronal cell loss, mild tomoderate vacuolation (A–C), astrogliosis (B), and diffuse PrPCWD deposition in the hippocampus (C) that
Thioﬂavin T failed to stain (D). Cerebellar neuropathology was more pronounced (E–H), with increased vacuolation (E), astrogliosis (F) and PrPCWD deposits (G), some of which were
stained with Thioﬂavin T (H). In contrast, hippocampal sections frommice inoculated with the original D10 isolate exhibited more extensive neuronal cell loss and vacuolation (I–K)
and astrogliosis (J), with dense, punctate plaques of PrPCWD (K) that stained sharply with thioﬂavin T (L), revealing more numerous amyloid structures that appeared punctate and
radially organized. Little or no cerebellar neuropathologywas observed in the brains of thesemice (M–P). Upon second passage (D10 p2), little to no neuronal cell loss and vacuolation
(Q–S) and mild to moderate astrogliosis (R) was evident in hippocampal sections, and PrPCWD deposition was much more diffuse (K) and lacked amyloidogenicity (T). However,
cerebellar neuropathology was clearly evident, with increased neuronal cell loss, vacuolation (U–W), and PrPCWD deposits (W), some of which were amyloidogenic, but lacked the
radially structured, punctate deposits found in D10 p1 plaques. Hippocampal sections from RML-infected wild-type mice exhibited vacuolation (Y) astrogliosis (Z) and diffuse PrPSc
deposition (AA) reminiscent of that produced by ampliﬁed D10 p1 and D10 p2 strains of CWD prions. Brain sections from D10-inoculaed PrP−/− mice were stained with H&E (AB),
GFAP (AC), anti-PrP (AD) and Thioﬂavin T (AE) as negative controls. Scale bars, 50 μm.
270 C. Meyerett et al. / Virology 382 (2008) 267–276consisted of substantial monoglycosylated PrPSc, while diglycosylated
PrPCWD constituted the vast majority of D10. Signiﬁcant amounts of di-
and monoglycosylated PrPCWD was observed in Amp D10 p1. Primarypassage of D10 into Tg(cerPrP)1536 mice (D10 p1) shifted the
glycoform ratio toward monoglycosylated PrPCWD, which was further
increased upon secondary passage (D10 p2). sPMCA of D10 also
Fig. 4. Strain adaptation changes CWD lesion proﬁles. Bar graphs displaying results of lesion proﬁle analyses for each prion strain at the indicated brain regions. PrP−/−mice inoculated
with D10 is shown as a baseline control. Radar plots shown to the right facilitate comparison of overall lesion proﬁles. Eachwedge of the plot represents the indicated brain region and
each concentric circle represents a severity point. Amp D10 p1, D10 p2 and RML share similar proﬁles that are distinct from the D10 p1 proﬁle.
271C. Meyerett et al. / Virology 382 (2008) 267–276shifted the glycoform ratio toward monoglycosylated PrPCWD. We did
observe some variability in these trends when we analyzed brain
homogenates from individual mice, especially among D10 p1 samples
(Fig. 5B). We therefore quantiﬁed band intensities from multiple
western blots to more accurately assess glycoform ratios of all prion
strains (Figs. 5C and D). The RML di:mono:unglycosylated PrPSc ratio
of 0.24±0.09:0.53±0.12:0.23±0.08 was drastically different from
those of all other strains (pb0.01). D10 consisted of a PrPCWD
glycoform ratio of 0.71±0.05:0.26±0.05:0.03±0.01. sPMCA of D10
produced ampliﬁed material with a glycoform ration of 0.74±
0.04:0.23±0.03:0.03±0.01, nearly identical to D10. Passage of serially
ampliﬁed D10 into Tg(cerPrP)1536 mice (Amp D10 p1) signiﬁcantly
changed the glycoform ratio to 0.49±0.05:0.35±0.04:0.16±0.03
(pb0.01 compared to D10), decreasing overall glycosylation. A similar
phenomenon occurred upon in vivo D10 adaptation. Primary passage
into Tg(cerPrP)1536 mice (D10 p1) slightly altered the glycoform ratio
to 0.66±0.21:0.24±0.14:0.10±0.08, while secondary passage (D10 p2)
signiﬁcantly shifted the ratio to 0.57±0.07:0.33±0.06:0.10±0.07
(pb0.05 for di- and monoglycosylated PrPCWD compared to D10).
These data reveal similar glycoforms ratios of Amp D10 p1 and D10 p2
prion inocula that are signiﬁcantly different from D10 and D10 p1
inocula.
sPMCA and mouse passage of D10 changes PrPCWD conformational
stability
We further characterized these prion inocula biochemically by
assessing conformational stability in the presence of GdnHCl, anotherestablished criteria for prion strain typing (Peretz et al., 2001, 2002;
Scott et al., 2005; Xie et al., 2006). We quantiﬁed PrPRES band
intensities from western blots of brain extracts incubated with
increasing GdnHCl concentrations then PK to determine the concen-
tration of GdnHCl required to PK digest 50% of PrPRES ([GdnHCl]50).
D10, mouse-passaged D10 (D10 p1) and serially-ampliﬁed D10
(sPMCA) exhibited nearly identical conformational stabilities, with
mean [GdnHCl]50 values of 2.35±0.01, 2.35±0.10 and 2.33±0.12 M,
respectively (Fig. 6). Conformational stability was signiﬁcantly
reduced upon secondary passage of D10 (D10 p2, 2.03±0.06 M,
pb0.01) and primary passage of ampliﬁed D10 (Amp D10 p1, 1.89±
0.06 M, pb0.01) in Tg(cerPrP)1536. The RML prion strain was signi-
ﬁcantly less stable than all other strains (1.46±0.01 M, pb0.01). In
toto, the biological, neuropathological and biochemical data reported
here strongly support the conclusion that D10 strain adaptation has
occurred in vitro and in vivo.
Discussion
The ﬁrst demonstration of amplifying PrPCWD using PMCA was
recently reported to yield an approximately 200-fold ampliﬁcation
efﬁciency per round (Kurt et al., 2007). In this study we have increased
this efﬁciency up to several thousand-fold per round by optimizing
NBH preparation and sonication parameters. We also demonstrated
the speciﬁcity of the reaction by using moPrPC substrates as negative
controls. We observed a linear relationship between −fold ampliﬁca-
tion and D10 dilutions between 10−3 and 2×10−5. Limiting substrate at
lower dilutions and limiting prion templates at higher dilutions
Fig. 5. Strain adaptation changes PrPCWD glycoform ratios. (A) Western blot of pooled brain homogenates (BH) from at least three mice demonstrates that the RML strain of mouse-
adapted scrapie consists of substantial monoglycosylated PrPSc (lane 2). The original D10 isolate of CWD prions contains primarily diglycosylated PrPCWD (lane 3). Pooled BH from
terminally sickmice inoculated with in vitro ampliﬁed D10 contains increasedmonoglycosylated PrPCWD compared to D10 (lane 4). Inoculation of D10 into Tg(cerPrP)1536mice shifts
glycoform ratios toward the monoglycosylated form upon primary (lane 6) and especially secondary (lane 7) passage. Similarly, sPMCA of D10 shifts the ratio toward the
monoglyosylated form (lane 8). Pooled BH from asymptomatic wild type mice inoculated with D10 contained no detectable PrPCWD (lane 4). (B) Western blot of individual BH
conﬁrms increasedmonoglycosylated PrPCWD of Amp D10 p1 (lanes 3–5) and D10 p2 (lanes 9 and 10), while D10 p1 is more variable (lanes 6–8). (C) Quantiﬁcation of band intensities
fromwestern blots displayed as a triplot of mean glycoform ratios±standard deviations for each group. Arrows indicate the axis to be read from points to determine the percent of
each glycoform. The glycoform ratio of D10 p1 (open circle) is not signiﬁcantly different from the original D10 ratio (black square), while the D10 p2 ratio is signiﬁcantly different
(black circle). sPMCA of D10 (open diamonds) producesmaterial displaying a glycoform ratio closely resembling both D10 and D10 p1. Passage of sPMCAD10 intoTg(cerPrP)1536mice
results in a further shift towards monoglycosylated PrPCWD (black diamonds), differing signiﬁcantly from D10 and resembling D10 p2. RML (black triangles) exhibited the greatest
proportion of monoglycosylation and was signiﬁcantly different than all other strains. (D) Triplot of raw data of at least six samples for each group used to generate the mean
glycoforms ratios in (C).
272 C. Meyerett et al. / Virology 382 (2008) 267–276probably account for asymptotic ampliﬁcation efﬁciencies. By main-
taining PrPCWD concentrations in the dynamic range of PMCA, we
were able to produce linear ampliﬁcation over repeated PMCA
rounds. This resulted in highly efﬁcient and reproducible ampliﬁca-
tion over at least eight PMCA rounds that generated signiﬁcant
amounts of ampliﬁed 10−24 D10 with which we infected Tg(cerPrP)
1536 mice. Comparing equal dilutions of the original D10 inoculum
and ampliﬁed 10−24 D10 by western blot conﬁrmed that both samples
displayed nearly identical signal intensities.
We next demonstrated the ﬁrst in vitro generation of infectious
CWD prions using ampliﬁed 10−24 D10 as the inoculum. In vitro-
ampliﬁed D10 elicited terminal prion disease earlier than the original
D10 used to seed the sPMCA reaction. This result was surprising
because generation of infectious hamster-adapted scrapie prions in
vitro using PMCA has previously been reported to elicit terminal
disease later than the original scrapie inocula, a phenomenon largely
abrogated by serial passage or by conjugation of ampliﬁed material to
nitrocellulose prior to inoculation (Castilla et al., 2005; Deleault et al.,
2007; Murayama et al., 2007a; Weber et al., 2007). One possible
explanation for this discrepancy is that previous studies used homo-
logous brain inocula, substrates and hosts, whereas we used infected
cervid brain as the prion inocula and Tg(cerPrP)1536 mice as a source
for brain substrate and host. Primary passage of cervid-derived D10
into a murine host may decrease prion replication efﬁciency, which
increases upon in vitro ampliﬁcation using NBH from Tg(cerPrP)1536mice as a substrate or secondary passage in Tg(cerPrP)1536 mice.
Indeed, we observed a reduction in mean incubation time to terminal
disease upon serial passage of D10 in Tg(cerPrP)1536 mice, in
accordance with another recent report (Green et al., 2008). These
data implicate other host factors present in the brain that may
inﬂuence prion ampliﬁcation in vitro and in vivo, resulting in nearly
identical CWD prion infectivity titres that we observed for sPMCA-
ampliﬁed and mouse-passaged D10. Many prion-forming cofactors
have been proposed, including proteins (Kaneko et al., 1997; Telling et
al., 1995; Yehiely et al., 1997), polysaccharides (Appel et al., 1999;
Dumpitak et al., 2005) or polyanions (Deleault et al., 2003, 2005) that
may facilitate host-speciﬁc prion ampliﬁcation in vitro and in vivo.
Another possibility postulated by Soto and colleagues is that in vitro-
generated scrapie prions may have created a new prion strain that
requires in vivo adaptation to acquire the same infectivity titre as the
original prion strain (Castilla et al., 2005). Our data supports this
hypothesis, but because sPMCA generated a cervid prion strain using
mouse NBH expressing cerPrPC, we conclude that strain adaptation
occurred in vitro, resulting in a more infectious prion strain in mice.
Correlation with our in vivo data demonstrating mouse adaptation of
D10 following serial passage strongly supports this interpretation.
Serial passage of natural sheep scrapie and bovine spongiform
encephalopathy prion isolates in Tg(ovPrP) mice has also recently
been shown to reduce incubation times (Baron and Biacabe, 2007;
Bencsik et al., 2007). As a corollary to the experiments conducted here,
Fig. 6. Strain adaptation changes PrPCWD conformational stability. Western blots of samples from the indicated prion strains treated with increasing concentrations of guanidine
hydrochloride (GdnHCl) and 50 μg/mL PK reveal that D10 retains its conformational stability after primary passage in Tg(cerPrP)1536 mice (D10 p1) or serial ampliﬁcation (sPMCA).
Secondary passage (D10 p2) or primary passage of ampliﬁed D10 (Amp D10 p1) destabilizes PrPCWD conformation, more closely resembling that of RML. Denaturation curves to the
right of each blot quantify PrPRES conformational stability (see Methods). The concentration of GdnHCl required to denature 50% of PrPRES ([GdnHCL]50), a measure of the
conformational stability, is shown to the right of the corresponding plot. Data are from at least three independent experiments using at least three animals per group.
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adapt natural scrapie isolates in vitro and increase their infectivity
titres as does in vivo adaptation via mouse passage.
Another straightforward explanation for the shortened incubation
times we observed is that inocula from in vitro ampliﬁcation and in
vivo adaptation contains no heterologous brain homogenate present
in the original D10 inoculum, abrogating a potential immune response
that may clear a signiﬁcant portion of the initial inocula. Seminal work
comparing mouse and hamster prion titres in mice showed that
hamster prions, containing heterologous hamster brain homogenate,
induced disease much earlier than mouse prions containing homo-
logous mouse brain homogenate, arguing against immune clearance
signiﬁcantly affecting prion titers (Büeler et al., 1993). Indeed, we have
never observed any clinical, cellular, biochemical or molecular
evidence of inﬂammation upon i.c. inoculation with heterologous
brain material (our unpublished data), most likely because the brain is
a relatively immune privileged site. In the present study, if immune
clearance simply lowered the effective D10 prion dose compared to in
vitro-ampliﬁed or mouse-passaged D10 without strain adaptation,
then both of these D10-derived strains should exhibit increased
infectivity titres while maintaining other strain properties of the
original D10. We explored this possibility by ﬁrst comparing
neuropathological properties of the original D10 strain, in vitro-
ampliﬁed and mouse-passaged D10, and RML. Both in vitro-ampliﬁed
and in vivo-adapted D10 prions induced similar neuropathology in Tg
(cerPrP)1536 mice, characterized by diffuse PrPCWD deposition that is
similar to that observed in brains from wild type mice infected with
RML, a scrapie strain well-adapted to the mouse (Chandler, 1961;
Kingsbury et al., 1983; Prusiner et al., 1978). These three prion strains
produced PrPCWD deposition clearly different than the dense, punctate
plaques evident in brains of Tg(cerPrP)1536 mice inoculated with theoriginal D10 strain. Similar diffuse PrPRES deposition has been
observed in RML-infected and CWD-infected mice expressing mouse
PrPC (Sigurdson et al., 2006; Zabel et al., 2007) and scrapie-infected
mice expressing bovine and mouse–bovine chimeric PrPC (Scott et al.,
2005). Ampliﬁed and mouse-passaged D10 and RML also produced
similar brain lesion proﬁles that were consistent with neuropathology
previously reported in scrapie-infected mice (Baringer and Prusiner,
1978; Eklund et al., 1967; Kingsbury et al., 1983) and distinct from the
proﬁle induced by the original D10 strain. The changes in location and
severity of prion lesions evident among these prion strains are
consistent with D10 strain adaptation by in vitro ampliﬁcation that is
indistinguishable from in vivo adaptation via passage of D10 in Tg
(cerPrP)1536 mice.
We also detected biochemical similarities among in vitro and in
vivo-adapted prion strains. While sPMCA D10 and D10 p1 displayed
nearly identical PrPCWD glycoforms ratios as the parental D10 strain,
Amp D10 p1 and D10 p2 signiﬁcantly increased monoglycosylated
PrPCWD compared to the principally diglycosylated D10 strain, similar
to the transition observed in another study of murine adaptation of
CWD prions (Sigurdson et al., 2006). These results are intriguing in
light of another recent study demonstrating that host PrPC glycoforms
dictate in vitro PrPSc ampliﬁcation efﬁciency (Nishina et al., 2006),
suggesting that perhaps murine PrPC glycoforms select, from a
heterologous mixture, distinct strains of CWD prions that are
preferentially ampliﬁed in vitro or in vivo. We also show that Amp
D10 p1 and D10 p2 conformations were signiﬁcantly more destabi-
lized by GdnHCl denaturation compared to sPMCA D10 and D10 p1,
the stabilities of which were nearly identical to that of D10. RML
adopted a conformation that was by far the least stable of all prion
strains investigated. Previous reports have documented relatively less
stable mouse-passaged scrapie prion conformations and more stable
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al., 2006). Our data demonstrate that serial passage of CWD prions in
Tg(cerPrP)1536 mice can destabilize their conformation, and that
sPMCA using Tg(cerPrP) NBH as substrate expedites this process.
Interestingly, decreased stability of in vitro and in vivo-adapted D10
prion strains correlates with shortened incubation times in Tg(cerprP)
1536 mice, a phenomenon previously exhibited for other novel prion
strains generated in vitro (Legname et al., 2005) and in vivo (Peretz et
al., 2002).
We did not observe statistically signiﬁcant changes in either
glycosylation or conformational stability of sPMCA D10 or D10 p1, as
one might expect if adaptation had occurred. Perhaps sPMCA and
primary passage of D10 initiates creation of a new or intermediate
prion strain, or selection of a small concentration of a pre-existing one
that, upon further passage into mice, is preferentially selected and
ampliﬁed. This interpretation is supported by the increased variability
in the biochemical properties of D10 p1 (glycosylation and conforma-
tional stability) and sPMCA (conformational stability), which may
indicate the emergence of nascent prion strains.
The similar neuropathological and biochemical characteristics of in
vitro and in vivo-adapted D10 that clearly differentiate them from
primary-passaged D10 prions strongly indicate that sPMCA has
adapted D10 as effectively as in vivo adaptation by mouse passage.
However, we cannot rule out the possibility that in vitro ampliﬁcation
and in vivo passage of D10 also increased the prion titre of these
strains, either by strain adaptation, immune abrogation, or both.
Unlike RML, whose titre has been determined by mouse bioassay and
cell culture assays (Klohn et al., 2003; Prusiner et al., 1982), exact titres
for most scrapie and all CWD prion strains have yet to be determined.
Comparing western blot signal intensities of PrPRES remains a crude
estimate of prion infectivity because PrPRES concentration and prion
infectivity do not always closely correlate (Hill et al., 1999; Rubenstein
et al., 1994). Here we present evidence for strain adaptation by sPMCA.
The possibility of a concomitant increase in prion titre would also be a
novel and interesting result of prion ampliﬁcation by sPMCA.
We conclude that in vitro D10 ampliﬁcation parallels primary pass-
age of D10 in Tg(cerPrP)1536 mice, and that sPMCA represents a viable
means of adapting prion strains to new hosts. Since strain adaptation
correlates with species barriers, we envision sPMCA to potentially be a
powerful tool with which to probe strain differences and assess species
barriers in a fraction of the time and cost of animal bioassays.
Materials and methods
Mice
FVB mice were purchased from the Jackson Laboratories (Bar
Harbor, ME). Tg(cerPrP)1536 and Tga20 mice were generated as
previously described (Browning et al., 2004; Fischer et al., 1996). All
mice were bred and maintained at Lab Animal Resources, accredited by
the Association for Assessment and Accreditation of Lab Animal Care
International, in accordance with protocols approved by the Institu-
tional Animal Care and Use Committee at Colorado State University.
Sources and preparation of prion inocula
The D10 isolate of CWD prions (D10) and the Rocky Mountain Lab
strain of mouse-adapted scrapie prions passage 5 (RML) were
previously described (Browning et al., 2004; Prusiner et al., 1978).
D10 was then passaged through Tg(cerPrP)1536 mice or ampliﬁed in
vitro by serial protein misfolding cyclic ampliﬁcation (sPMCA). 10%
brain homogenates were prepared in PBS or PMCA buffer (4 mM
EDTA, 150 mM NaCl in PBS). Densitometric analysis of PK-digested
samples on western blots revealed similar band intensities of equal
dilutions of D10, mouse-passaged D10, ampliﬁed 10−24 D10 and RML.
We therefore diluted equal volumes of each inoculum 1:10 in 320 mMsucrose supplemented with 100 U/mL Penicillin and 100 μg/mL
Streptomycin (Gibco) in PBS 30min prior to intracerebral inoculations.
Preparation of normal brain homogenate (NBH) and PMCA
Micewere euthanized and perfused with 30ml 5 mM EDTA in PBS.
Whole brains were removed and immediately frozen in liquid
nitrogen. Brains were weighed and transferred into 1.5 mL Eppendorf
tubes with 2.5 mm glass beads. PMCA buffer with 2× Complete
Protease Inhibitor Cocktail (Roche) was added to make a 20% w/v
solution. Samples were homogenized for 20 s at 4.5 m/s in a FastPrep
machine (Biogene), cooled on ice for 2 min and centrifuged at
14,000 ×g for 10 s to reduce foaming. This process was repeated twice.
NBH was diluted to a 10% w/v solution by adding an equal volume of
PMCA conversion buffer containing 2% Triton X-100 and incubated on
ice for 20 min. NBH was clariﬁed by centrifuging for 30 s at 1500 ×g
and supernatants were aliquoted to into new tubes and stored at
−70 °C. PMCA was modiﬁed from a previous protocol (Kurt et al.,
2007). Brieﬂy, 50 μL samples of D10 diluted into 10% NBH were placed
into wells of a 96-well microplate. The entire plate was suspended in
the water bath of a 3000MP sonicator (Misonix) and sonicated at 70–
85% maximum power for 40 s, followed by a 30-minute incubation at
37 °C. This cyclewas repeated 96 times. For sPMCA, 50 μL of a 10−3 D10
dilution in NBH was subjected to PMCA. 50 μL of a 10−3 dilution of
ampliﬁed material in fresh NBH was subjected to another PMCA
round. This process was repeated for a total of eight rounds.
PK digestion and western blotting
Samples were digested with 50 μg/ml PK (Roche) for 30 min at
37 °C. The reaction was stopped by adding lithium dodecyl sulfate
sample loading buffer (Invitrogen) and incubating at 95 °C for 5 min.
Proteins were electrophoretically separated through 12% sodium
dodecyl sulfate-polyacrylamide gels (Invitrogen), and transferred to
polyvinylidene diﬂuoride membranes (Millipore). Non-speciﬁc mem-
brane binding was blocked by incubation in 5% milk blocking solution
(Bio-Rad) for 1 h. Membranes were then incubated for 1 h at room
temperaturewith horseradish peroxidase-conjugated Bar224 anti-PrP
monoclonal antibody (SPI bio) diluted 1:20,000 in Superblock (Pierce),
washed 6×10min in PBS with 0.2% Tween 20, and incubated for 5 min
with enhanced chemiluminescent substrate (Millipore). Membranes
were digitally photographed using the FujiDoc gel documentation
system equipped with a cooled charge-coupled diode camera (Fuji).
Densitometric analyses were performed using Quantity One software
(Bio-Rad).
Prion inoculations and clinical scoring
Mice were anesthetized by Isoﬂuorane inhalation. Thirty micro-
liters of each inoculum was injected intracerebrally 3 mm deep
through the coronal suture 3–5 mm lateral of the sagittal suture. Mice
weremonitored daily for clinical symptoms of prion disease, including
tail rigidity, impaired extensor reﬂex, akinesia, tremors, ataxia, weight
loss and paralysis. Mice with any four of these symptoms were scored
terminally sick and euthanized.
Histochemistry and immunohistochemistry (IHC)
Tissues were ﬁxed in 10% paraformaldehyde, embedded in parafﬁn
and 5–10 μm sections mounted on glass slides. For PrP staining tissue
sections were deparafﬁnized, treated with concentrated formic acid
for 30min, then autoclaved at 121 °C in target retrieval solution (Dako)
for 2 h, washed 2×2min in 1× PBS, treatedwith 0.3% H202 inmethanol
for 10 min and blocked for 15 min with 1% BSA in PBS. Sections were
then incubated with horseradish peroxidase-conjugated anti-PrP Bar
224 monoclonal antibody diluted 1:100 in antibody diluent (Dako) for
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(Dako) for 2 min, rinsed 2×2 min in PBS and counterstained with
hematoxylin. Slides were dehydrated in xylene and coverslips
mounted with Cytoseal (Richard Allan Scientiﬁc). For Thioﬂavin T
staining, sections were treated with 1% Thioﬂavin T in distilled water
for 10min at room temperature, followed by 1% acetic acid inwater for
10 min and then rinsed with distilled water for 5 min. Hematoxylin
and Eosin (H&E) and glial ﬁbrillary acidic protein (GFAP) staining was
performed on a NexES automated IHC stainer (Ventana Medical
systems, Inc. Tucson, AZ). Sections were stained with H&E for 4 min at
room temperature. Sections were stained with rabbit polyclonal
antisera against GFAP (diluted 1:8) for 10 min at 37 °C followed by
Biotinylated goat anti-rabbit Ig (mouse/rat adsorbed) for 8 min, then
counterstained with hematoxylin for 4 min. Sections were visualized
and digitally photographed using an Olympus BX60 microscope
equipped with a cooled charge-coupled diode camera.
Lesion proﬁling
Brain lesion proﬁling was performed as previously described
(Fraser and Dickinson, 1968) with slight modiﬁcations. Ten neuroa-
natomic regions were identiﬁed in medial sagittal brain sections from
at least six mice of each group: 1—dorsal medulla, 2—cerebellum, 3—
superior colliculus, 4— red nucleus, 5—hypothalamus, 6—hippocam-
pus, 7—thalamus, 8—cerebral cortex, 9—primary somatosensory
cortex and 10—caudate–putamen. Four investigators blinded to
group identiﬁcation scored each region for vacuolation, astrogliosis
and PrPRES deposition using the following severity scale: normal (0–1),
mild (2), moderate (3) and severe (4). The average of the sum of the
three scores constitutes the severity score for each region.
Conformational stability assay
Conformational stability assays were modiﬁed from a previous
protocol (Xie et al., 2006). 15 μl aliquots of brain homogenates were
incubated for 1 h at room temperature with increasing concentrations
of guanidine hydrochloride (GdnHCl, Sigma) ranging from 0 to 3.75 M
in 0.375 M increments. Samples were precipitated in ice-cold
methanol at −20 °C overnight, centrifuged at 13,000 ×g for 30 min
at 4 °C. Pellets were washed in PMCA buffer and centrifuged 3×,
resuspended in 18 μl of PMCA buffer, PK-digested andwestern blotted.
Conformational stability was quantiﬁed by densitometric analyses of
western blots, plotting the mean percentage of PrPRES remaining ±SD
as a function of GdnHCl concentration, and using fourth order
polynomial equations and nonlinear regression (GraphPad Prism) to
ﬁt denaturation curves for each prion strain.
Statistical analyses
One-way ANOVA with Tukey post-test analysis was performed
using GraphPad Prism.
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